AgomAb Therapeutics NV Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Selling, General & Admin	18.28	12.79	10.13	6.1
Research & Development	49.82	48.88	39.31	26.31
Other Operating Expenses	-2.16	-2.39	-1.42	-1.22
Total Operating Expenses	65.94	59.28	48.02	31.19
Operating Income	-65.94	-59.28	-48.02	-31.19
Interest Income	4.6	1.72	1.27	0.3
Interest Expense	-0.27	-0.13	-0.36	-0.09
Other Non-Operating Income (Expense)	-5.04	-4.86	0.85	18.96
Total Non-Operating Income (Expense)	-0.71	-3.27	1.76	19.18
Pretax Income	-66.65	-62.55	-46.26	-12.01
Provision for Income Taxes	-	-	-0	0.62
Net Income	-66.65	-62.55	-46.26	-12.63
Net Income to Common	-66.65	-62.55	-46.27	-11.39
Net Income Growth	-	-	-	-
Shares Outstanding (Basic)	21	1	1	1
Shares Outstanding (Diluted)	21	1	1	1
Shares Change	3716.54%	-	-	-
EPS (Basic)	-80.16	-143.22	-107.09	-35.63
EPS (Diluted)	-80.16	-143.22	-107.09	-35.63
EPS Growth	-	-	-	-
Free Cash Flow	-56.73	-51.75	-47.5	-24.59
Free Cash Flow Growth	-	-	-	-
Free Cash Flow Per Share	-2.75	-95.62	-87.79	-45.45
EBITDA	-65.75	-59.06	-47.71	-31.09
EBIT	-65.94	-59.28	-48.02	-31.19
Effective Tax Rate	-	0.00%	0.01%	-5.15%

SEC Filings: 10-K · 10-Q